BioSpace News Archive

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today reported financial results for the second quarter ended June 30, 2020 and provided a general business update.

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced today that Andy Wade is stepping down from the position of Chief Financial Officer (CFO

Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and TriclonicsTM), today announced financial results for the second quarter that ended June 30, 2020, and provided a business update.

AMN Healthcare Services, Inc., the leader and innovator in total talent solutions for healthcare organizations across the United States, announced its second quarter 2020 financial results.

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter ended June 30, 2020.

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results and a corporate update for the second quarter ended June 30, 2020.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA for Injection, today reported financial results for the quarter ended June 30, 2020, and provided a corporate update

Collaboration highlights the power and versatility of the proprietary Switch-Blocker technology, which may be applied to molecular diagnostics in COVID-19 and other infectious diseases, in addition to oncology applications currently commercialized and in development [06-August-2020] SAN DIEGO , Aug. 6, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading com

Submitted a New Drug Application to the U.S. Food and Drug Administration for the review of tenapanor as a first-in-class therapy to control serum phosphorus in adult patients with chronic kidney disease on dialysis Maintains strong balance sheet with $204.8 million in cash, cash equivalents and short-term investments

Urovant Sciences (Nasdaq: UROV) announced today that it will report 2020 first fiscal quarter financial results after the close of U.S. financial markets on Thursday, August 13, 2020. Management will host a conference call to discuss Urovant’s financial results at 1:30 p.m. Pacific / 4:30 p.m. Eastern that same day. A question and answer session will follow management’s remarks. The con